Vol 31, No 1 (2024)
Review Article
Published online: 2023-09-29

open access

Page views 578
Article views/downloads 300
Get Citation

Connect on Social Media

Connect on Social Media

Quality of life in heart failure: New data, new drugs and devices

Katarzyna Major1, Aleksandra Bodys-Pełka23, Marcin Grabowski2, Małgorzata Lelonek1
Pubmed: 37822076
Cardiol J 2024;31(1):156-167.

Abstract

Quality of life (QoL) is a therapeutic goal in heart failure. There are many EBM therapies for improving QoL. In this study, data is presented on new pharmacotherapies and devices that impact QoL in the heart failure population.

Article available in PDF format

View PDF Download PDF file

References

  1. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  2. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  3. The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med. 1995; 41(10): 1403–1409.
  4. Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995; 16(1): 51–74.
  5. Xiao-Jun L, I-Mei L, Sheng-Yu F. Methodological issues in measuring health-related quality of life. Tzu Chi Med J. 2013; 25(1): 8–12.
  6. Kosiborod M, Soto GE, Jones PG, et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007; 115(15): 1975–1981.
  7. Iqbal J, Francis L, Reid J, et al. Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail. 2010; 12(9): 1002–1008.
  8. Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013; 61(4): 391–403.
  9. Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50(8): 768–777.
  10. Mosoiu D, Rogozea L, Landon A, et al. Palliative care in heart failure: a public health emergency. Am J Ther. 2020; 27(2): e204–e223.
  11. Evangelista LS, Moser DK, Westlake C, et al. Impact of obesity on quality of life and depression in patients with heart failure. Eur J Heart Fail. 2006; 8(7): 750–755.
  12. Vaduganathan M, Fonarow GC, Greene SJ, et al. Health-related quality of life in comorbid heart failure with reduced ejection fraction and diabetes mellitus. J Am Coll Cardiol. 2019; 74(25): 3176–3178.
  13. Benes J, Kotrc M, Jarolim P, et al. The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2021; 8(2): 1417–1426.
  14. Celano CM, Villegas AC, Albanese AM, et al. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018; 26(4): 175–184.
  15. O'Connor CM, Jiang W, Kuchibhatla M, et al. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010; 56(9): 692–699.
  16. Angermann CE, Gelbrich G, Störk S, et al. MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. 2016; 315(24): 2683–2693.
  17. Taylor RS, Walker S, Smart NA, et al. ExTraMATCH II Collaboration. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol. 2019; 73(12): 1430–1443.
  18. Palmer K, Bowles KA, Paton M, et al. Chronic heart failure and exercise rehabilitation: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2018; 99(12): 2570–2582.
  19. Weinfurt K, Flynn K, Piña I, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301(14): 1451–1459.
  20. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995; 273(18): 1450–1456.
  21. Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017; 10(8): e003430.
  22. Haddad H, Bergeron S, Ignaszewski A, et al. Canadian real-world experience of using sacubitril/valsartan in patients with heart failure with reduced ejection fraction: insight from the PARASAIL study. CJC Open. 2020; 2(5): 344–353.
  23. de Diego C, González-Torres L, Núñez JM, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018; 15(3): 395–402.
  24. Rohde LE, Chatterjee NA, Vaduganathan M, et al. Sacubitril/Valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis. JACC Heart Fail. 2020; 8(10): 844–855.
  25. Fernandes ADF, Fernandes GC, Ternes CMP, et al. Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction. Heart Rhythm O2. 2021; 2(6Part B): 724–732.
  26. Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011; 151(2): 218–224.
  27. Docherty KF, Shen Li, Castagno D, et al. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020; 22(3): 528–538.
  28. Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021; 42(31): 3011–3020.
  29. Cohen JB, Schrauben SJ, Zhao L, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020; 8(3): 172–184.
  30. Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2018; 104(5): 407–415.
  31. Chandra A, Vaduganathan M, Lewis EF, et al. PARAGON-HF Investigators. Health-Related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart Fail. 2019; 7(10): 862–874.
  32. Shah SJ, Cowie MR, Wachter R, et al. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021; 23(9): 1541–1551.
  33. Cosín J, Díez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002; 4(4): 507–513.
  34. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the emperor-reduced trial. Circulation. 2021; 143(4): 326–336.
  35. Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461.
  36. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation. 2022; 145(3): 184–193.
  37. Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021; 144(16): 1284–1294.
  38. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28(3): 568–574.
  39. Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation. 2022; 146(4): 279–288.
  40. Do TN, Do QH, Cowie MR, et al. Effect of the optimize heart failure care program on clinical and patient outcomes: the pilot implementation in Vietnam. Int J Cardiol Heart Vasc. 2019; 22: 169–173.
  41. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  42. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
  43. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020; 141(2): 90–99.
  44. Kosiborod Mikhail. Presented at ESC Heart Failure 2022. MD, pooled analysisform DEFINE-HF and PRESERVED-HF.
  45. Ostrominski JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur J Heart Fail. 2022; 24(10): 1892–1901.
  46. Solomon SD, McMurray JJV, Claggett B, et al. DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12): 1089–1098.
  47. Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022; 146(16): 1210–1224.
  48. Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022; 28(9): 1956–1964.
  49. Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022; 28(4): 809–813.
  50. Yu CM, Chan JYS, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009; 361(22): 2123–2134.
  51. Chan JY, Fang F, Zhang Q, et al. Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial. Eur Heart J. 2011; 32(20): 2533–2540.
  52. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014; 64(2): 182–192.
  53. Howard C, Jullian L, Joshi M, et al. TAVI and the future of aortic valve replacement. J Card Surg. 2019; 34(12): 1577–1590.
  54. Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI Trial Investigators, SURTAVI Trial Investigators, SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017; 376(14): 1321–1331.
  55. Maciver J, Ross HJ. Quality of life and left ventricular assist device support. Circulation. 2012; 126(7): 866–874.
  56. Slaughter MS, Rogers JG, Milano CA, et al. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23): 2241–2251.
  57. Dokainish H, Teo K, Zhu J, et al. INTER-CHF Investigators. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. 2017; 5(7): e665–e672.
  58. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart. 2002; 87(3): 235–241.
  59. Park J, Moser DK, Griffith K, et al. Exploring symptom clusters in people with heart failure. Clin Nurs Res. 2019; 28(2): 165–181.
  60. Salyer J, Flattery M, Lyon DE. Heart failure symptom clusters and quality of life. Heart Lung. 2019; 48(5): 366–372.
  61. Arian M, Mirmohammadkhani M, Ghorbani R, et al. Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis. Qual Life Res. 2019; 28(2): 321–334.
  62. Gupta A, Allen LA, Bhatt DL, et al. Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure. JAMA Cardiol. 2018; 3(1): 44–53.
  63. Sears SF, Woodrow L, Cutitta K, et al. A patient's guide to living confidently with chronic heart failure. Circulation. 2013; 127(13): e525–e528.
  64. Heo S, Lennie TA, Okoli C, et al. Quality of life in patients with heart failure: ask the patients. Heart Lung. 2009; 38(2): 100–108.
  65. Greene SJ, Butler J, Spertus JA, et al. Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction. JAMA Cardiol. 2021; 6(5): 522–531.
  66. Książczyk M, Lelonek M. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Heart Fail Rev. 2020; 25(3): 393–402.
  67. Dębska-Kozłowska A, Książczyk M, Lelonek M. Where are we in 2021 with heart failure with reduced ejection fraction? Current outlook and expectations from new promising clinical trials. Heart Fail Rev. 2022; 27(2): 419–430.
  68. Dębska-Kozłowska A, Książczyk M, Lelonek M. New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. Adv Med Sci. 2022; 67(1): 95–102.